Zenas BioPharma, Inc. (ZBIO)
29.53
+1.27
(+4.49%)
USD |
NASDAQ |
Nov 09, 14:42
Zenas BioPharma Shareholders Equity (Quarterly) : 212.31M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 212.31M |
| June 30, 2026 | 247.10M |
| March 31, 2026 | 335.83M |
| December 31, 2025 | 242.14M |
| September 30, 2025 | 196.43M |
| June 30, 2025 | 239.63M |
| Date | Value |
|---|---|
| March 31, 2025 | 284.32M |
| December 31, 2024 | 312.46M |
| September 30, 2024 | 359.44M |
| June 30, 2024 | 160.83M |
| March 31, 2024 | -2.409M |
| December 31, 2023 | 24.36M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.387B |
| Alnylam Pharmaceuticals, Inc. | 3.604B |
| Anika Therapeutics, Inc. | 137.58M |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 384.17M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 675.22M |
| Total Liabilities (Quarterly) | 462.91M |
| Debt to Equity Ratio | 1.884 |
| Current Ratio | 9.422 |
| Net Debt Paydown Yield | -4.37% |